The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Differentiated human NBs are associated with better outcome and lower stage; induction of differentiation is considered to be therapeutically advantageous. All-trans retinoic acid (ATRA) has been shown to induce the differe...
Guardado en:
Autores principales: | Peihua Luo, Meili Lin, Lin Li, Bo Yang, Qiaojun He |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f86a46d7b81941268a708b2d126926ae |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases
por: Amit Kumar Halder, et al.
Publicado: (2021) -
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
por: Fabricio de Carvalho, et al.
Publicado: (2011) -
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Melissa K. Bennett, et al.
Publicado: (2022) -
Oxycodone self-administration activates the mitogen-activated protein kinase/ mitogen- and stress-activated protein kinase (MAPK-MSK) signaling pathway in the rat dorsal striatum
por: Christopher A. Blackwood, et al.
Publicado: (2021) -
Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound
por: Karolina Łuczkowska, et al.
Publicado: (2021)